Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Gynecologic Cancer

Rucaparib for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (CO-338-017)
A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status Conditions Phase Study ID
Recruiting Ovarian Cancer
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer
Phase II CO-338-017
NCT01891344
Summary

The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.


Investigator
Elizabeth Swisher, MD
Location    
Seattle Cancer Care Alliance 800-804-8824  
Eligibility Criteria (must meet the following to participate in this study)
  • Confirmed diagnosis of high-grade epithelial ovarian (serous or endometrioid histology), fallopian tube, or primary peritoneal cancer
  • Relapsed/progressive disease as confirmed by CT scan
  • Received ≥1 prior platinum-based treatment regimen
  • Received platinum-based regimen as last treatment; continuous or switch maintenance treatment as part of this regimen is permitted
  • Sensitive to last platinum regimen (disease progression >6 months after the last dose of platinum)
  • If <55 years of age at diagnosis, prior history of breast cancer, or close relative (first or second degree) with ovarian cancer or early onset (<age 50) breast cancer, must have been previously tested for gBRCA mutation; after 15 patients harboring the gBRCA mutation are enrolled, no additional patients with a known gBRCA mutation will be allowed to enroll.
  • Have biopsiable and measurable disease
Exclusions (conditions that would prevent participation in this study)
  • History of prior cancers except for those that have been curatively treated, with no evidence of cancer currently (provided all chemotherapy was completed >6 months prior and/or bone marrow transplant >2 years prior to first dose of rucaparib).
  • Prior treatment with any PARP inhibitor
  • Symptomatic and/or untreated central nervous system metastases
  • Pre-existing duodenal stent and/or any other gastrointestinal disorder or defect that would, in the opinion of the Investigator, interfere with absorption of rucaparib

Other exclusion criteria may apply.

Last Updated
July 07, 2014
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.